The impact of diabetes on prescription drug costs: The population-based Turin study

Diabetologia

Volumn 51, Issue 5, 2008, Pages 795-801

  Bruno, G ^a   Karaghiosoff, L ^b   Merletti, F ^c   Costa, G ^b   De Maria, M ^d   Panero, F ^a   Segre, O ^a   Cavallo Perin, P ^a   Gnavi, R ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Epidemiology Unit   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Regional Environmental Protection Agency   (Italy)

Author keywords

Cost of illness; Costs; Drugs; Economics; Health expenditures; Survey

Indexed keywords

ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; REGISTRIES; URBAN POPULATION;

EID: 41849140781     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-0957-4     Document Type: Article

References (25)

1. Orszag PR, Ellis P (2007) Addressing rising health care costs-a view from the Congressional Budget Office. N Engl J Med 357:1885-1887
2. Zhang P, Engelgau MM, Norris SL, Gregg EW, Venkat Narayan KM (2004) Application of economic analysis to diabetes and diabetes care. Ann Intern Med 140:972-977
3. Hogan P, Dall T, Nikolov P, American Diabetes Association (2003) Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932
4. Jönsson B, CODE-2 Advisory Board (2002) Revealing the cost of type II diabetes in Europe. Diabetologia 45:S5-S12
5. Williams R, Van Gaal L, Lucioni C, CODE-2 Advisory Board (2002) Assessing the impact of complications on the costs of type II diabetes. Diabetologia 45:S13-S17
6. Pogach LM, Hawley G, Weinstock R et al (1998) Diabetes prevalence and hospital and pharmacy use in the Veterans Health Administration (1994). Use of an ambulatory care pharmacy-derived database. Diabetes Care 21:368-373
7. Weinstock RS, Hawley G, Repke D, Feuerstein BL, Sawin CT, Pogach LM (2004) Pharmacy costs and glycemic control in the Department of Veterans Affairs. Diabetes Care 27(Suppl 2):B74-B81
8. Brandle M, Zhou H, Smith BR et al (2003) The direct medical cost of type 2 diabetes. Diabetes Care 26:2300-2304
9. Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH (2002) The economic cost of diabetes in Canada, 1998. Diabetes Care 25:1303-1307
10. Davis WA, Knuiman MW, Hendrie D, Davis TM (2006) The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Intern Med J 36:155-161
11. Henriksson F, Agardh CD, Berne C et al (2000) Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 248:387-396
12. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW (2006) Diabetes prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 23:299-305
13. Koster I, von Ferber L, Ihle P, Schubert I, Hauner H (2006) The cost burden of diabetes mellitus: the evidence from Germany. The CoDiM study. Diabetologia 49:1498-1504
14. Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G (1988) Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care 21:389-397
15. Rathmann W, Haastert B, Icks A, Giani G (2007) Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004. Diabetes Care 30:848-853
16. Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD (2000) Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 23:770-774
17. Oliva J, Lobo F, Molina B, Monereo S (2004) Direct health care costs of diabetic patients in Spain. Diabetes Care 27:2616-2621
18. Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G (2008) Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study. Nutr Cardiovasc Dis DOI 10.1016/j.numecd.2007.11. 004
19. Gnavi R, Karaghiosoff L, Dalmasso M, Bruno G (2006) The Piedmont Diabetes Register: opportunities and limits for epidemiological purposes. Epidemiol Prev 30:59-64
20. AMD, SID, Diabete Italia (2007) Standards italiani per la cura del diabete mellito. Linee guida e raccomandazioni. http://www.siditalia.it/ documenti/AMD_SID_04.pdf, accessed 19 February 2008
21. Istituto Superiore di Sanità (2007) Risultati nazionali dello studo QUADRI (QUalita dell'Assestenza alle persone Dibetiche nelle Regioni Italiane). http://www.epicentro.iss.it/igea/pdf/Istisan_Quadri.pdf, accessed 19 February 2008
22. Bruno G, Cerutti F, Merletti F et al (2005) Residual beta-cell function and male/female ratio are higher in incident young adults than in children: the registry of type 1 diabetes of the Province of Turin, Italy, 1984-2000. Diabetes Care 28:312-317
23. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J (2005) Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 46:1080-1087
24. Campbell HM, Boardman KD, Dodd MA, Raisch DW (2007) Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model. Ann Pharmacother 41:1101-1110
25. Crivera C, Suh DC, Huang ES et al (2006) The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients. Curr Med Res Opin 22:2301-2311